» Articles » PMID: 36007985

Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function

Abstract

Background: A familial predisposition to sudden and/or arrhythmic death (SAD) in the setting of coronary artery disease (CAD) exists; however, the genetic basis is poorly understood.

Objectives: The purpose of this study was to determine whether a genome-wide polygenic score for coronary artery disease (GPS) might have utility in SAD risk stratification in CAD patients without severe systolic dysfunction.

Methods: A previously validated GPS was generated utilizing genome-wide genotyping in 4,698 PRE-DETERMINE participants of European ancestry with CAD and left ventricular ejection fraction >30%-35%. The population was dichotomized according to top GPS decile as defined by the general population, and absolute, proportional, and relative risks for SAD and non-SAD were estimated using competing risk analyses.

Results: Over a median follow-up of 8.0 years, participants in the top GPS decile were at elevated absolute SAD risk (8.0%; 95% CI: 5.1%-12.4% vs 4.8%; 95% CI: 3.3%-7.0%; P = 0.005) and proportional SAD risk (29% vs 16%; P = 0.0003) compared with the remainder. After controlling for left ventricular ejection fraction, clinical factors, and electrocardiogram parameters, the top GPS decile was associated with SAD (subdistribution HR: 1.77; 95% CI: 1.23-2.54; P = 0.002) but not non-SAD (subdistribution HR: 1.00; 95% CI: 0.80-1.25; P = 0.98) (P for Δ = 0.003). The addition of the top GPS decile to the multivariable model significantly improved net reclassification indexes (NRIs) (continuous NRI: 14.0%; P = 0.024; and categorical NRI: 6.6%; P = 0.005) but not the C-index (difference in C-index: 0.007; P = 0.143).

Conclusions: Among CAD patients without severe systolic dysfunction, high GPS specifically predicted SAD and enriched for both absolute and proportional SAD risk, identifying a population who might benefit from defibrillator therapy.

Citing Articles

Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders.

Kember R, Davis C, Feuer K, Kranzler H J Clin Invest. 2024; 134(20).

PMID: 39403926 PMC: 11473164. DOI: 10.1172/JCI172882.


Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts.

Peek N, Hindricks G, Akbarov A, Tijssen J, Jenkins D, Kapacee Z Eur Heart J. 2024; 45(43):4616-4626.

PMID: 39378245 PMC: 11560274. DOI: 10.1093/eurheartj/ehae326.


Coronary artery calcium and sudden cardiac death: current evidence and future directions.

Razavi A, Whelton S, Blumenthal R, Sperling L, Blaha M, Dzaye O Curr Opin Cardiol. 2023; 38(6):509-514.

PMID: 37581228 PMC: 10908356. DOI: 10.1097/HCO.0000000000001081.


Sudden death in ischemic heart disease: looking for new predictors: polygenic risk.

Boccanelli A, Scardovi A Eur Heart J Suppl. 2023; 25(Suppl B):B31-B33.

PMID: 37091639 PMC: 10120966. DOI: 10.1093/eurheartjsupp/suad078.


Does polygenic risk for substance-related traits predict ages of onset and progression of symptoms?.

Kranzler H, Feinn R, Xu H, Ho B, Saini D, Nicastro O Addiction. 2023; 118(9):1675-1686.

PMID: 37069489 PMC: 10525011. DOI: 10.1111/add.16210.

References
1.
Solomon S, Chatterjee N . Who Benefits From Implantable Cardioverter-Defibrillators?: Integrating Absolute, Proportional, and Competing Risk. J Am Coll Cardiol. 2017; 69(21):2619-2621. DOI: 10.1016/j.jacc.2017.04.006. View

2.
Delgado C, Baweja M, Crews D, Eneanya N, Gadegbeku C, Inker L . A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021; 32(12):2994-3015. PMC: 8638402. DOI: 10.1681/ASN.2021070988. View

3.
Kaikkonen K, Kortelainen M, Linna E, Huikuri H . Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation. 2006; 114(14):1462-7. DOI: 10.1161/CIRCULATIONAHA.106.624593. View

4.
Merchant F, Levy W, Kramer D . Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use. J Am Heart Assoc. 2020; 9(5):e015139. PMC: 7335546. DOI: 10.1161/JAHA.119.015139. View

5.
Khera A, Chaffin M, Aragam K, Haas M, Roselli C, Choi S . Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018; 50(9):1219-1224. PMC: 6128408. DOI: 10.1038/s41588-018-0183-z. View